Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in Switzerland

OBJECTIVE: The study aim was to evaluate the cost effectiveness and budget impact of siponimod compared to interferon beta-1a for adult patients with secondary progressive multiple sclerosis (SPMS) with active disease, from a Swiss health insurance perspective. METHODS: We conducted an analysis usin...

Descripción completa

Detalles Bibliográficos
Autores principales: Schur, Nadine, Gudala, Kapil, Vudumula, Umakanth, Vadapalle, Sreelatha, Bhadhuri, Arjun, Casanova, Alain, Adlard, Nicholas, Schwenkglenks, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079303/
https://www.ncbi.nlm.nih.gov/pubmed/33791945
http://dx.doi.org/10.1007/s40273-021-01023-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079303/
https://www.ncbi.nlm.nih.gov/pubmed/33791945
http://dx.doi.org/10.1007/s40273-021-01023-8

Ejemplares similares